Menopause-indexed cardiovascular risk assessment
Menopause-indexed cardiovascular risk assessment evaluates cardiovascular risk against a woman's hormonal life stage rather than a sex-neutral risk model, treating age at menopause, premature ovarian insufficiency and pregnancy complications including pre-eclampsia and gestational diabetes as cardiovascular risk markers. The 2020 American Heart Association scientific statement established the menopause transition as a period of accelerating risk in which the timing of prevention matters. Delivery ranges from structured risk consultations inside European menopause bilans to hospital women's heart programs with imaging and provocation testing. Protocols are not yet standardized across operators. Evidence tier: emerging.
What it is
Menopause-indexed cardiovascular risk assessment evaluates a woman's cardiovascular risk against her hormonal life stage rather than against a sex-neutral risk model. The distinguishing feature versus general preventive cardiology is the indexing: risk is read in relation to reproductive history and menopausal status, so that age at menopause, premature ovarian insufficiency, surgical menopause, and pregnancy complications such as pre-eclampsia and gestational diabetes are treated as cardiovascular risk markers in their own right rather than as obstetric history. The 2020 American Heart Association scientific statement on the menopause transition established the clinical basis: the transition itself is a period of accelerating cardiovascular risk, and the timing of preventive intervention matters. In delivery the modality ranges from a structured risk consultation with lipids, blood pressure and glycemic markers read against menopausal stage, through to hospital women's heart programs with dedicated imaging and provocation testing. Assessment protocols are not yet standardized across operators, which is why the evidence tier is emerging even though the underlying risk science is well established.
Who it is for
Women in perimenopause and postmenopause, and particularly those with early menopause before 45, premature ovarian insufficiency, surgical menopause, or a history of hypertensive disorders of pregnancy, pre-eclampsia, gestational diabetes or preterm birth, all of which carry elevated long-term cardiovascular risk that sex-neutral risk calculators tend to under-weight. Women with autoimmune disease, and those who have had cardiotoxic cancer treatment, are also served by the hospital programs delivering this modality. The population most poorly served by conventional risk scoring, and therefore most likely to benefit from indexing, is women in their forties and early fifties whose absolute short-term risk reads as low while their trajectory does not.
What to expect
A structured assessment covers reproductive and menopausal history alongside conventional risk factors, then blood pressure, a lipid panel including where available apolipoprotein B, glycemic markers, and body composition. Operators differ substantially beyond that baseline. Some add carotid ultrasound or ankle-brachial pressure index as a vascular measure; Matilda International Hospital in Hong Kong includes ankle-brachial pressure index in its priced women's programme. Academic centres add cardiac imaging, and in a small number of cases provocation testing for coronary microvascular dysfunction and non-obstructive coronary disease, conditions that disproportionately affect women and that standard angiography can miss. Output is a risk assessment read against hormonal stage with a prevention plan, and where indicated referral into cardiology. Several European operators deliver it inside a broader menopause bilan alongside bone densitometry and cancer screening rather than as a standalone product.
History and background
Cardiovascular disease has long been the leading cause of death in women, and women typically develop coronary heart disease several years later than men, a lag historically attributed to estrogen. Longitudinal cohort work through the 2000s and 2010s, notably the Study of Women's Health Across the Nation, established that the menopause transition is itself associated with adverse changes in lipids, body composition, vascular stiffness and fat distribution, independent of chronological ageing. The 2020 American Heart Association scientific statement consolidated that evidence and argued for early, timed prevention across the transition. In parallel, cardio-obstetrics emerged as a named clinical field treating pregnancy as a cardiovascular stress test whose complications predict lifelong risk. Delivery followed the science: dedicated women's heart programs are now established at several North American academic centres, and named cardiovascular units are appearing inside European and Latin American menopause clinics.
Worth knowing
This is the fastest-emerging axis in the women's health pillar; a year earlier it would have been a thin column. The most concise statement of the thesis found anywhere in the sweep behind this branch comes from a Geneva hospital describing three key moments in a woman's hormonal life: contraception, pregnancy and menopause. Only two operators in the entire global sweep name both a cardiovascular unit and a bone unit inside a single menopause programme, one in Madrid and one in Santiago, which shows how rare the full healthspan configuration still is. The clinical trio that reliably separates a genuine women's heart programme from a marketing page is spontaneous coronary artery dissection, microvascular angina and pre-eclampsia: pages that name those are describing a service, pages that do not are usually describing an intention.
Offered across the Atlas 13
Related modalities